This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Nuvilex Highlights The Technology And Advances Behind The Cutting-Edge Cell-in-a-Box® Technology Platform

Nuvilex, Inc. (OTCQB: NVLX), an emerging biotechnology provider of cell and gene therapy solutions through its ongoing acquisition of the assets of SG Austria, today discussed the proprietary Cell-in-a-Box® technology, providing additional information about the science and technology behind the product.

Creation of Cell-in-a-Box® was a technological concept over 20 years ago, originally designed for studying potential ways to create protection for cells and destruction of viruses through neutralizing antibody production. This concept soon became a reality and developed over time to have a wide variety of uses, some of which are still being realized. In the past decade, this concept has advanced to the point we can now fully address the enormous humanitarian value and applications as well as substantial clinical potential for treatment of an extremely diverse set of diseases.

The founding principle was to develop an artificial, semi-permeable capsule with sufficient permeability that oxygen and nutrients could reach encapsulated cells while cellular products could be released into the bloodstream or adjacent tissues. In addition, the capsule material had to remain robust, yet restrictive enough to exclude antibodies and immune cells. Otherwise, antibodies or immune cells would cause or allow recognition of the foreign capsule material, or the cells inside, and ultimately cause rejection and destruction of the live cellular implant.

After substantial research, initial capsules were created which offered strength and durability. The SG Austria Cell-in-a-Box® patented encapsulation platform uses natural cotton, or cellulose sulphate, as the building blocks for the capsule itself, ultimately providing an optimum permeability balance. One of the best and most exciting properties was that the resulting capsules were non-allergenic. Additional intervening years included advances in purification, manufacturing, and chemistry of the cellulose sulphate to enable careful manipulation of the materials to allow specific size and characteristic capsules to be made.

Over time, advances in material science made it possible to vary the capsule size giving rise to a range from ~0.7 to 1.4 cm in diameter, about the size of the head of a pin. Further refinement has produced an extremely robust, yet flexible material. This capability enables varying numbers of cells to be placed inside each capsule, anywhere from a few cells to 10,000 or more cells. Even specific pore sizes can be created for the capsule based on the application. This unusual feature therefore provides an ability to limit or regulate what components or constituents can enter and exit the capsules.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG

Markets

DOW 17,841.98 -86.22 -0.48%
S&P 500 2,080.15 -9.31 -0.45%
NASDAQ 4,919.6440 -19.6830 -0.40%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs